Last reviewed · How we verify
SC MNTX
At a glance
| Generic name | SC MNTX |
|---|---|
| Sponsor | Bausch Health Americas, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. (PHASE4)
- Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan (PHASE1)
- Open-Label Treatment Extension of Protocol MNTX 301 (PHASE3)
- Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose (PHASE1)
- Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function (PHASE1)
- Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction (PHASE2)
- Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function (PHASE1)
- Open-Label Treatment Extension of Protocol MNTX 302 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC MNTX CI brief — competitive landscape report
- SC MNTX updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI